<?xml version="1.0" encoding="UTF-8"?>
<p id="par0205">This delay is especially relevant for MERS patients, as they have a much shorter median time interval between symptom onset and death than do SARS patients 
 <xref rid="bib0695" ref-type="bibr">139</xref>, 
 <xref rid="bib0210" ref-type="bibr">42</xref>. The use of recombinant interferon Î²-1b, which has the lowest EC
 <sub>50</sub>/Cmaxratio against MERS-CoV among tested preparations of recombinant interferons, should be evaluated in combination with other effective antivirals in clinical trials at early stages of the infection 
 <xref rid="bib0415" ref-type="bibr">83</xref>, 
 <xref rid="bib0420" ref-type="bibr">84</xref>.
</p>
